EUVIMEDEUVIMED entdecken
Crossref

Fatty Liver Disease Along Cushing Syndrome Evolution

Maria Marengo, Claire Briet, Mathilde Munier, Jérôme Boursier, Patrice Rodien iD, Valentine Suteau iD

The Journal of Clinical Endocrinology & Metabolism · 2025

DOI: 10.1210/clinem/dgae568 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2025. Verfasst von Maria Marengo und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Diabetology and Nutrition, Angers University Hospital, 49100 Angers, France. Hauptthemen laut MEDLINE: Cushing Syndrome, Fatty Liver, Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 40 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

The clinical manifestations of Cushing syndrome are variable, but an important number of patients present a metabolic syndrome, strongly associated with hepatic steatosis.

Objective

The aim of this study was to determine the prevalence of metabolic dysfunction associated steatotic liver disease (MASLD) at the diagnosis of Cushing syndrome.

Methods

We conducted a single-center retrospective study at Angers Hospital (France) between 2010 and 2020. Forty-nine patients followed for Cushing syndrome with available abdominal imaging at diagnosis were included. A mean liver/spleen density ratio < 1 on computed tomography was diagnostic of hepatic steatosis. Simple clinico-biological scores predictive of hepatic fibrosis (FIB-4, NAFLD Fibrosis Score, and eLIFT) were calculated for patients with hepatic steatosis.

Results

Of the 49 patients, 13 (26.5%) had hepatic steatosis at diagnosis of Cushing syndrome. All 13 had MASLD. These patients had a higher prevalence of type 2 diabetes and higher triglyceride levels in multivariate analysis. There was no difference according to the intensity or duration of Cushing syndrome. Among the 13 patients with MASLD, 2 (15.4%) had a significant fibrosis predictive score. Of the 4 patients with follow-up imaging after remission of Cushing syndrome, 3 had remission of steatosis between 1 and 5 years after remission of Cushing syndrome. No patient without MASLD at diagnosis had a worsening liver/spleen ratio after remission.

Conclusion

We estimated the prevalence of hepatic steatosis at the diagnosis of Cushing syndrome at 26.5%. The presence of metabolic factors was associated with the occurrence of hepatic steatosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cushing SyndromeFatty LiverNon-alcoholic Fatty Liver DiseaseHumansMaleFemaleRetrospective StudiesMiddle AgedAdultPrevalenceFranceAgedLiver CirrhosisFollow-Up StudiesMetabolic SyndromePrognosis

Stichwörter der Autor:innen

CushingMASLDhepatic steatosis

Autor:innen und Institutionen

  • Department of Endocrinology, Diabetology and Nutrition, Angers University Hospital, 49100 Angers, France.
  • Angers University, MITOVASC, CarMe team, CNRS UMR 6015, INSERM U1083, 49100 Angers, France.
  • Centre de Référence des Maladies Rares de la Thyroïde et des Récepteurs Hormonaux, University Hospital Angers, 49100 Angers, France.
  • Department of Hepato-Gastroenterology, Angers University Hospital, 49100 Angers, France.
  • HIFIH Laboratory, Angers University, UPRES EA3859, SFR 4208, 49100 Angers, France.

ORCID-Profile: Patrice Rodien, Valentine Suteau

Zitieren

APA

Marengo, M., Briet, C., Munier, M., Boursier, J., Rodien, P., & Suteau, V. (2025). Fatty Liver Disease Along Cushing Syndrome Evolution. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgae568

Vancouver

Marengo M, Briet C, Munier M, Boursier J, Rodien P, Suteau V. Fatty Liver Disease Along Cushing Syndrome Evolution. The Journal of Clinical Endocrinology & Metabolism. 2025. doi:10.1210/clinem/dgae568

BibTeX
@article{Marengo2025,
  author = {Marengo, Maria and Briet, Claire and Munier, Mathilde and Boursier, Jérôme and Rodien, Patrice and Suteau, Valentine},
  title = {Fatty Liver Disease Along Cushing Syndrome Evolution},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2025},
  doi = {10.1210/clinem/dgae568}
}
Kostenlos starten →